Jakafi is designated as an orphan drug in the United States and the European Union for treating myelofibrosis and polycythemia vera [1]. This designation grants specific benefits and incentives to encourage the development of treatments for rare diseases [2].
What are the conditions Jakafi is approved to treat?
Jakafi is approved for adult patients with myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. It is also indicated for adult patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea [1].
What benefits come with orphan drug designation?
Orphan drug designation provides incentives such as a period of market exclusivity following approval, tax credits for qualified clinical research and development expenses, and assistance from regulatory agencies in the design of clinical trials [2]. For Jakafi, this has meant a 7-year period of market exclusivity in the US and a 10-year period in the EU for its approved indications [1][3].
When does Jakafi's market exclusivity end?
In the United States, Jakafi's orphan drug exclusivity for myelofibrosis and polycythemia vera expired in November 2021 [1][3]. In the European Union, the 10-year market exclusivity for orphan drugs generally ends in 2024 [3].
What are the next steps for Jakafi after exclusivity ends?
Following the expiration of market exclusivity, the pathway opens for the potential development and approval of generic or biosimilar versions of Jakafi. This can lead to increased competition and potentially lower prices for the medication [4].
How does Jakafi work?
Jakafi is a Janus kinase (JAK) inhibitor. It works by blocking the activity of JAK enzymes, which are involved in signaling pathways that regulate blood cell growth and immune function. In myeloproliferative neoplasms like myelofibrosis and polycythemia vera, these pathways can be overactive, leading to abnormal blood cell production and disease symptoms [1].
Are there alternatives to Jakafi for these conditions?
For myelofibrosis, other JAK inhibitors exist, and treatments may also involve stem cell transplantation. For polycythemia vera, options can include phlebotomy, hydroxyurea, and interferon therapy, in addition to JAK inhibitors like Jakafi [5].
Who manufactures Jakafi?
Jakafi (ruxolitinib) is manufactured by Incyte Corporation [1].
What is the typical cost of Jakafi?
The cost of Jakafi can be substantial, with prices varying based on insurance coverage, pharmacy, and dosage. Patient assistance programs are often available through the manufacturer to help offset costs [6].
What clinical data supports Jakafi's use?
Clinical trials have demonstrated Jakafi's efficacy in reducing spleen volume, improving symptom burden, and prolonging overall survival in patients with myelofibrosis [1]. For polycythemia vera, studies showed it effectively reduced hematocrit levels and spleen size, and improved quality of life [1].
What are the potential side effects of Jakafi?
Common side effects of Jakafi include low blood cell counts (anemia, thrombocytopenia, neutropenia), diarrhea, increased cholesterol levels, and muscle pain [1]. More serious risks can include serious infections, blood clots, and the development of other cancers [1].